Rare clinical experiences for surgical treatment of melanoma with osseous metastases in Taiwan by Huang, Kuo-Yuan et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Musculoskeletal Disorders
Open Access Research article
Rare clinical experiences for surgical treatment of melanoma with 
osseous metastases in Taiwan
Kuo-Yuan Huang1, Chrong-Reen Wang2 and Rong-Sen Yang*3
Address: 1Department of Orthopaedics and Institute of Clinical Medicine, College of Medicine, National Cheng Kung University Medical Center, 
Tainan city, Taiwan, 2Section of Rheumatology and Immunology, Department of Internal Medicine, College of Medicine, National Cheng Kung 
University Medical Center, Tainan city, Taiwan and 3Department of Orthopaedics, College of Medicine, National Taiwan University Medical 
Center, Taipei city, Taiwan
Email: Kuo-Yuan Huang - hkyuan@mail.ncku.edu.tw; Chrong-Reen Wang - wangcr@mail.ncku.edu.tw; Rong-Sen Yang* - rsyang@ntuh.gov.tw
* Corresponding author    
Abstract
Background: Malignant melanoma occurs infrequently in Taiwan. Once it has progressed into
osseous metastases, the prognosis is poor. There are no reported clinical experiences of surgical
management in this area.
Methods: To improve our understanding of the rare clinical experiences, we retrospectively
investigated clinical characteristics, radiological findings, treatment modalities, survival outcomes
and prognoses of 11 Taiwanese patients with osseous metastasis of melanoma treated surgically at
two national medical centers, National Taiwan University Hospital and National Cheng Kung
University Hospital from January 1983 to December 2006.
Results: Six patients suffered from acral-lentiginous melanoma. Nine patients sustained multiple
osseous metastases and most lesions were osteolytic. Nine patients also had sustained metastases
to other organs including liver, lungs, lymph nodes, brain and spleen. Second malignancies including
lung cancer, thyroid papillary carcinoma, renal cell carcinoma and cervical cancer co-existed in four
patients. The interval from the initial diagnosis of melanoma to the clinical detection of osseous
metastases varied from 0–37.8 months (mean 9.75 months). Metastatic melanoma was invariably
fatal; the mean survival time from bone metastases to death was 5.67 months.
Conclusion: Due to the high morbidity and poor survival of Taiwanese patients with osseous
metastases of melanoma, surgical treatment should be directed towards pain relief and the
prevention of skeletal debilitation in order to maintain their quality of life.
Background
After melanoma has grown radially and superficially in
the epidermis and on mucosal surfaces, it can metastasize
to any organ or tissue such as the lungs and bone, where
melanoma metastases are common [1,2]. Melanoma
most frequently occurs in fair-skinned Caucasian individ-
uals older than 40 years who have numerous moles [3]. In
most countries, the incidence of melanoma has been
increasing recently, with annual incidences reaching 3–
7% among fair-skinned populations [3,4]. In the United
States, the incidence of melanoma has increased more
than that of any other cancer [5]. An estimated 60,000
new cases of melanoma are diagnosed each year with
more than 8,000 annual deaths in the United States;
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about one in 75 persons will develop this cancer in their
lifetime [5,6]. After osseous metastases occur, the patient's
survival is usually short-term [7,8]. In addition, bone
metastases of melanoma predispose patients to patholog-
ical fractures of axial and appendicular skeletons, bone
marrow failure and neurological deficits. These complica-
tions substantially increase their pain and result in a poor
quality of life [6,7,9].
Despite its high mortality rate, melanoma is not well stud-
ied in Asians, with only a limited number of reported
cases [10]. Acral-lentiginous melanoma (ALM) is the most
common subtype of melanoma in Asian populations
including Taiwanese [11]. The diagnosis of this subtype is
often delayed [11,12]. We conducted this retrospective
chart review in two national medical centers in Taiwan to
improve our understanding of the incidence, treatment
and outcomes of osseous metastases of melanoma in Asia.
Methods
The hospital records of the National Taiwan University
Hospital and the National Cheng Kung University Hospi-
tal from January 1983 to December 2006 were surveyed to
identify cases of malignant melanoma. We reviewed the
charts, medical records, surgical notes, radiological
images and pathology records of patients diagnosed with
osseous metastases. A total of 11 patients underwent sur-
gical intervention for osseous metastases. Surgical indica-
tions in our series included an intractable skin ulcer,
mechanical instability due to pathologic fractures, neuro-
logical deterioration due to neural compression by metas-
tases, pain unresponsive to nonoperative measures such
as radiation and the need for biopsy material for his-
topathological verification of the diagnosis. The choice of
surgical procedure depended on the patients' individual
clinical situation, location of the tumor, medical comor-
bidities and overall prognosis. Surgical treatments
included wide excision (four patients), posterior laminec-
tomy for decompression and posterior instrumentation
(one patient), below-the-knee amputation (two patients),
above-the-knee amputation (one patient), ray amputa-
tion (one patient) and intralesional excision plus internal
fixation with cement augmentation (two patients) (Tables
1 &2).
All patients had histopathological proof of bone metas-
tases. Table 1 lists the locations of their osseous metas-
tases, and Table 2 shows the operations performed.
Adjuvant therapies after surgical treatment varied depend-
ing on the patient's age, the sites and number of metas-
tases, disease progression, the patient's overall medical
condition and the patient's intentions for further manage-
ment. Table 2 lists the adjuvant therapies including chem-
otherapy with or without tamoxifen (six patients),
radiotherapy (five patients) and immunotherapy with
Bacillus Calmette-Guérin (BCG), interferon alpha or IL-2
(three patients).
We compiled data on the age and sex distribution of these
patients, their primary lesions, clinical sizes, microscopic
classification with depth of invasion (Clark level), bone
metastases and complications, radiographic manifesta-
tions, other metastases, synchronous tumors, usages of
analgesic medications, interval from initial diagnosis to
occurrence of osseous metastases, interval from diagnosis
to death and survival after the occurrence of bone metas-
tases.
Results
The 11 patients (six men and five women) ranged in age
from 39–79 years (mean 61.8 years) at the time of diagno-
sis of melanoma. Six patients had the ALM subtype. The
metastases of the melanoma were correlated with the
severity of the primary cutaneous lesions (Table 1). One
patient who did not possess a primary cutaneous lesion
had a melanoma of the navicular bone (Fig. 1), with an
initial presentation of dull pain in the right midfoot that
lasted six months. Most patients had pain and weakness
in the involved regions. Osteolytic bone lesions were radi-
ographically detected in 10 patients. Osteosclerosis of the
thoracolumbar spine was also found (Table 1). Most
lesions in the long bones were multiple, eccentric and
oval, with clinically significant cortical erosion (Fig. 2).
Two patients had permeated osteolytic lesions; such a pat-
tern was characterized by numerous, tiny radiolucencies
between the trabeculae of the residual bones. Periosteal
reactions and dystrophic calcifications were found in one
patient with multiple sites of bony destruction in the
ileum and sacrum.
The osseous metastases were in the axial skeleton in eight
patients, six of whom had spinal metastases. Two patients
had osseous metastases to the cervical spine, four to the
thoracic spine, six to the lumbar spine, two to the scapula,
three to the ribs, four to the pelvis and three to the skull.
Compression fractures with epidural compression
occurred in three patients with spinal metastases. One
patient received posterior laminectomy for decompres-
sion and posterior instrumentation because of progressive
muscle power weakness of right lower limb (Fig. 3). The
other two patients received irradiation instead of laminec-
tomy because of their poor medical condition. The appen-
dicular skeletons were involved in six patients, with bone
metastases to the femur in four patients, to the tibia in two
and to the navicular bone in one. Four patients had path-
ological fractures including one each in the subtro-
chanteric region of the femur, the midshaft of the femur,
the midshaft of the tibia, and the navicular bone. Two
patients with femoral fractures were successfully treated
with intralesional excision and internal fixation with com-B
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Table 1: Clinical, pathological and radiographic data
Patient age 
(years)
Sex Primary 
tumor
Clinical size 
(cm)
Microscopic 
classification
Depth 
(Clark level)
Osseous metastases and 
complications
Radiographic manifestation Other metastases Synchronous 
tumor
45 F Scalp 1.5 × 1.0 Malignant melanoma V Frontoparietal skull, multiple 
cervico- thoracolumbar spine 
(compression fractures of 
thoracolumbar spine), bone 
marrow infiltration
Multiple spinal metastases 
with bony destruction and 
cord compression
Liver, bone 
marrow
None
72 M L anterior 
chest wall
1.5 × 1.5 Malignant melanoma IV 5th lumbar vertebra, R acetabulum L5 compression fracture 
with bony destruction
Lung, Lymph 
nodes
None
64 M R sole 1.5 × 1.5 acral lentiginous 
melanoma
V L skull base, midcervical, mid 
thoracolumbar spine
Multiple bony destruction, 
permeative osteolytic skull 
lesion
Lung None
79 M L sole 1.0 × 1.0 acral lentiginous 
melanoma
III R scapular, thoracolumbar spine 
(L2 compression fracture), L 
sacroiliac joint, pelvic rim and 
bilateral femurs
Multiple bony destruction 
with periosteal reaction and 
dystrophic calcifications
Lymph nodes Lung cancer
62 M L sole 2.3 × 2.1 acral lentiginous 
melanoma
IV L ninth rib, thoracolumbar spine Sclerotic lesions in 
thoracolumbar spine
Liver Thyroid papillary 
carcinoma, renal 
cell carcinoma
67 F R heel 3.5 × 1.0 acral lentiginous 
melanoma
V R femoral pathological fracture, R 
knee, L mid femur, R scapular, rib
Permeative osteolytic change Lymph node, lung, 
liver
None
70 F L lower leg 1.0 × 1.0 Malignant melanoma IV L femoral subtrochanteric fracture Osteolytic bony destruction Liver, spleen Renal cell 
carcinoma
67 M R foot 7.0 × 6.0 acral lentiginous 
melanoma
V R tibia, proximal femur Increased tracer uptake over 
R proximal femur
Lung, lymph 
nodes
None
39 F L subungual 1.1 × 0.9 acral lentiginous 
melanoma
V Skull, thoracolumbar spine, 
thoracic cage, pelvic rim
Osteolytic bony destruction Liver, lung, lymph 
nodes, brain
None
74 F L lower limb 1.0 × 0.8 Malignant melanoma V L midtibial pathological fracture, 
sacroiliac joint
Osteolytic bony destruction Lung Cervical cancer
51 M Unknown NA Malignant melanoma NA R navicular pathological fracture Comminuted fracture Liver, lung, lymph 
nodes
None
L, left; R, right; NA, not applicable.BMC Musculoskeletal Disorders 2007, 8:70 http://www.biomedcentral.com/1471-2474/8/70
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pression hip screws and Küntscher nailing augmented
with cement fixation. The patient with the tibia fracture
was treated with above-the-knee amputation because of
multiple skin lesions and ulcers. The patient with the
navicular fracture underwent conservative treatment with
chemotherapy alone because of the coexistence of several
distant metastases.
All 11 patients had metastases other than osseous metas-
tases from their melanomas. Four patients had a synchro-
nous malignancy including one lung cancer, one thyroid
papillary carcinoma, two renal cell carcinomas and one
cervical cancer. The synchronous malignancy usually
occurred first and then co-existed with the melanoma
(Table 1). The use of analgesic medications was decreased
after the operations, and most patients reported signifi-
cant alleviation of pain after surgical intervention. Dra-
matic pain relief was achieved in three patients with
pathological fractures who received internal fixation.
The interval from the diagnosis of melanoma to the detec-
tion of osseous metastases varied from 0–37.8 months
(mean 9.75 months) (Table 2). The prognosis of patients
with melanoma and osseous metastases was generally
poor. After osseous metastasis had been diagnosed, the
mean survival was only 5.67 months (Table 2). We found
no significant differences in prognosis between the axial
and appendicular osseous metastases (mean survival 5.44
and5.72 months, respectively). The average survival time
of males (6.88 months) was longer than females (4.21
months). There was no obvious correlation between age
and survival. The survival time of six patients with the
ALM subtype averaged 5.40 months, which was only
slightly shorter than that of the other five patients (5.99
months). Even in patients with a synchronous tumor, the
prognosis did not deteriorate. There were no distinct dif-
ferences in survival among patients receiving chemother-
apy, radiotherapy and/or immunotherapy.
Discussion
Osseous metastases of malignant melanoma are rare
among Asians [10,11]. Six of our patients had ALM, which
has the predilection to occur on the palms, soles and sub-
ungual nail beds. Such a distribution usually delays diag-
nosis and patients accordingly have worsened prognoses.
Indeed, presently we found that the survival time of ALM
patients (5.4 months) was slightly shorter than that of
other subtypes (5.99 months). Osseous metastases from
malignant melanoma usually occur in patients with rela-
tively advanced primary lesions and multiple bony
lesions at the time of diagnosis [12-14], as shown in the
histopathological findings of our series with a Clark level
of III, IV or V. Until now, there has not been evidence to
support the conclusion that the surgical treatment con-
Table 2: Surgical treatments and outcomes
Patient 
age 
(years)
Sex Surgical treatment Therapy Time (months)
Diagnosis to bone 
metastases
Diagnosis to death Bone metastases 
to death
45 F Wide excision Radiotherapy 1.77 7.44 5.67
72 M Posterior laminectomy for 
decompression, vertebroplasty with 
PMMA cement, posterior 
instrumentation
Radiotherapy, 
chemotherapy, IL-2
16 17.27 1.27
64 M Below-knee amputation Radiotherapy, BCG, 
chemotherapy
14.00 18.27 4.27
79 M Wide excision, transposition flap, 
lymph node dissection
Radiotherapy 15.90 21.87 5.97
62 M Wide excision None 0.70 16.40 15.70
67 F Wide excision, groin dissection, 
ORIF with Küntscher nailing and 
cement augmentation
Radiotherapy 37.80 38.97 1.17
70 F ORIF with CHS and bone cement 
augmentation
Chemotherapy 8.87 13.67 4.80
67 M Below-knee amputation Chemotherapy 3.57 7.77 4.20
39 F Ray amputation Interferon and 
tamoxifen
6.20 7.30 1.10
74 F Above-knee amputation Chemotherapy 2.43 10.76 8.33
51 M None* Chemotherapy 0.00 9.87 9.87
BCG, Bacillus Calmette-Guérin; ORIF, open reduction and internal fixation.
*Diagnosed with fine-needle biopsy.BMC Musculoskeletal Disorders 2007, 8:70 http://www.biomedcentral.com/1471-2474/8/70
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tributes to the survival of metastatic melanoma patients
[1,8,15]. Therefore, management is directed towards the
relief of symptoms and the maintenance of a good quality
of life in patients with osseous metastases of melanoma.
Primary melanoma of the bone has been rarely reported
in the literature [16]. In isolated appendicular osseous
metastases of melanoma, survival may be prolonged after
aggressive surgical resection of the metastatic bony focus
[17]. Common sites for osseous metastases of melanoma
include the vertebrae, skull, pelvis, thoracic cage and prox-
imal parts of the femur [18-22]. Osseous metastases gen-
erally occur in the axial skeleton; reflecting this, there were
eight cases among the 11 patients presently studied. Spi-
nal metastases may result in vertebral compression frac-
tures, epidural or cord compression (Fig. 3) [6,7,9]. For
patients with neurological deficits such as paraplegia or
cauda equina syndrome, the neurological decompression
to relieve symptoms and recover functions should be con-
sidered as health permits. Moreover, simultaneous instru-
mentation or vertebroplasty with
polymethylmethacrylate (PMMA) cement can provide
spinal stability to alleviate back pain in patients with
pathological vertebral fractures. Intralesional excision or
curettage of osseous metastatic melanoma lesions
together with open reduction and internal fixation with
PMMA cement augmentation might be an effective strat-
egy for the surgical management of pathological fractures
in the appendicular skeleton. Two patients in our series
received such an intervention and obtained significant
pain relief. Metastatic lesions within the long bones are
usually multiple, osteolytic, eccentric and oval, and are
associated with clinically significant cortical erosion [15];
this was evident in our cases (Fig. 2). Lesions usually
appear first in the medullary cavity, and then spread to
destroy the bone trabeculae, extend to the cortex and
finally lead to pathological fractures (Fig. 2) [14,15].
However, such radiographic features in our patients were
similar to those in other cancers.
Because melanoma with osseous metastases is heteroge-
neous in its biology, treatment plans must be highly indi-
(a). Plain radiograph of a 74-year-old woman Figure 2
(a). Plain radiograph of a 74-year-old woman. The radio-
graph reveals a pathologic fracture at the diaphysis of the left 
tibia due to an osteolytic lesion in the medullary cavity. (b). 
T1-weighted magnetic resonance image showing several tibial 
lesions that are eccentric, oval and associated with clinically 
significant cortical erosion. (c). T1-weighted magnetic reso-
nance image demonstrating a hypointense lesion with endo-
steal scalloping of the tibia and cortical erosion.
Magnetic resonance image of lumbosacral spine showing a  compression fracture of L5 of posterior bulging contour with  enhancement and epidural soft tissue mass over the anterior  epidural space with marked compression of the thecal sac Figure 3
Magnetic resonance image of lumbosacral spine showing a 
compression fracture of L5 of posterior bulging contour with 
enhancement and epidural soft tissue mass over the anterior 
epidural space with marked compression of the thecal sac.
Pathologic fracture of the right naviculum in a 51-year-old  man with melanoma presented at the initial visit Figure 1
Pathologic fracture of the right naviculum in a 51-year-old 
man with melanoma presented at the initial visit.BMC Musculoskeletal Disorders 2007, 8:70 http://www.biomedcentral.com/1471-2474/8/70
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vidualized. Surgical management is generally followed by
adjuvant therapies such as chemotherapy, radiation ther-
apy or immunotherapy. Single or combined chemother-
apy does not improve survival in advanced-stage disease,
as evident presently and reported previously [1,8,10].
External beam radiotherapy is effective in preventing local
recurrence of malignant melanoma and can provide palli-
ative treatment for metastatic melanoma [23]. In our
cases, irradiation of the affected areas relieved pain con-
siderably for several months without affecting the growth
of tumor, similar to previous reports [10,15]. Significant
proportions of melanoma cells express estrogen receptors,
which leds to a supportive role for tamoxifen in the treat-
ment of metastatic melanoma [8]. Given their immuno-
logic effects, low-dose interleukin-2, granulocyte-
monocyte colony stimulating factor and interferon alpha-
2b produce durable remissions in patients with metastatic
melanoma, and they have been used as postoperative
adjuvant therapies [24]. Therefore, the goal of surgical
treatment for osseous metastases of melanoma should be
directed towards the palliation of symptoms, particularly
if the anticipated relief of related symptoms exceeds the
potential adverse effects of the therapy. Symptomatic
metastases in weight-bearing bones require special con-
sideration. For large lesions or cortical destruction, pro-
phylactic stabilization and irradiation are preferred.
Alternatively, the lesion may be treated with radiation
alone and patients are monitored for evidence of patho-
logic fractures. Unless the risk of surgery is high or the
expected life span is short, pathologic fractures of weight-
bearing bones should be stabilized to maximize the qual-
ity of life and decrease hospital costs. Furthermore, surgi-
cal resection can produce an immediate decrease in tumor
burden at a reasonable expenditure [25].
Bisphosphonates such as pamidronate and zoledronic
acid have been used for palliative therapy in patients with
osteolytic lesions metastasized from multiple myeloma or
metastatic breast cancer. The aim is to prevent or delay the
onset of skeletal complications [26,27]. Moreover,
bisphosphonates can reduce bone pain in patients with
bony metastases [28]. Zoledronic acid has demonstrated
efficacy in the treatment of bone metastases in patients
with prostate cancer, lung cancer or other solid tumors
[26]. The bisphosphonate pamidronate induces apoptosis
in human melanoma cells in vitro [29]. In an in vivo ani-
mal study, incadronate inhibited bone resorption by
increasing numbers of apoptotic osteoclasts [30]. In addi-
tion, incadronate can substantially suppress the growth of
human melanoma cells, increase the numbers of apopto-
sis of tumor cells and decrease the tumor-associated
blood-vessel density [30]. Therefore, bisphosphonate
therapy might be an alternative to surgery or an adjuvant
treatment for osseous metastatic melanoma in the future.
The prognosis of patients with melanoma is related to the
extent and the stage of the tumor. Early detection and
management of melanoma are the key factors to improve
overall survival. The prognosis is poor after melanoma
progresses and undergoes osseous metastasis [2,31].
Osseous metastases of melanoma may predispose indi-
viduals to pathologic fractures in the axial or appendicular
bones or to bone marrow failure and may substantially
influence the quality of life and survival expectancy of
patients. For Asian patients with melanoma, the mean
survival after the diagnosis of osseous metastases was 5.67
months in our series, which was longer than 4.7 months
reported in Caucasian populations [2,7,31].
Conclusion
In conclusion, osseous metastases of melanoma are rare
in Taiwan and the prognoses of patients are as poor as
with Caucasians. Surgical intervention is effective in pro-
viding pain relief, especially for those with pathological
fracture and those receiving internal fixation. Due to the
high morbidity and poor survival, surgical treatment
should be directed towards pain relief and the prevention
of skeletal debilitation in order to maintain a patient's
quality of life.
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